Xu Peng
Emergency Department, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Int J Gen Med. 2025 Aug 25;18:4709-4734. doi: 10.2147/IJGM.S539237. eCollection 2025.
Sepsis is a global health challenge, affecting millions annually and remaining a leading cause of mortality in intensive care units. Gut microbiota plays a complex role in the onset and progression of sepsis, with its alterations reflecting disease severity. Recently, modulating gut microbiota and its metabolites has emerged as a promising therapeutic strategy for sepsis. This review highlights the role of gut microbiota in sepsis and systematically identifies key immune response targets directly influenced by gut microbiota metabolites, such as short-chain fatty acids (SCFAs), bile acids, and indoleacetic acid, among other important metabolites. Additionally, it offers a full overview of current research on gut microbiota-regulated therapeutic approaches, including fecal microbiota transplantation (FMT) and artificial intelligence (AI) applications. These insights offer a novel perspective for advancing the understanding of sepsis pathogenesis and its treatment.
脓毒症是一项全球性的健康挑战,每年影响数百万人,并且仍然是重症监护病房中主要的死亡原因。肠道微生物群在脓毒症的发生和发展中起着复杂的作用,其变化反映了疾病的严重程度。最近,调节肠道微生物群及其代谢产物已成为脓毒症一种有前景的治疗策略。本综述强调了肠道微生物群在脓毒症中的作用,并系统地确定了受肠道微生物群代谢产物直接影响的关键免疫反应靶点,如短链脂肪酸(SCFAs)、胆汁酸和吲哚乙酸等其他重要代谢产物。此外,它全面概述了目前关于肠道微生物群调节治疗方法的研究,包括粪便微生物群移植(FMT)和人工智能(AI)应用。这些见解为增进对脓毒症发病机制及其治疗的理解提供了新的视角。